TR201009397A2 - Pharmaceutical compositions containing rosuvastatin. - Google Patents

Pharmaceutical compositions containing rosuvastatin.

Info

Publication number
TR201009397A2
TR201009397A2 TR2010/09397A TR201009397A TR201009397A2 TR 201009397 A2 TR201009397 A2 TR 201009397A2 TR 2010/09397 A TR2010/09397 A TR 2010/09397A TR 201009397 A TR201009397 A TR 201009397A TR 201009397 A2 TR201009397 A2 TR 201009397A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
compositions containing
containing rosuvastatin
rosuvastatin
particles
Prior art date
Application number
TR2010/09397A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09397A priority Critical patent/TR201009397A2/en
Priority to EP11725996A priority patent/EP2566465A2/en
Priority to PCT/TR2011/000135 priority patent/WO2011139256A2/en
Priority to PCT/TR2011/000249 priority patent/WO2012064307A1/en
Publication of TR201009397A2 publication Critical patent/TR201009397A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Abstract

Mevcut buluş etken madde olarak rosuvastatin ve/veya farmasötik olarak kabul edilebilir bir tuzunu içeren farmasötik partiküller ve bu partiküllerin ateroskleroz, hiperkolesterolemi, hiperlipoproteinemi, hipertrigliseridemi, miyokard enfarktüsü tedavisi ve/veya önlenmesinde kullanılacak bir ilacın üretiminde kullanılması ile ilgilidir.The present invention relates to pharmaceutical particles comprising rosuvastatin as active ingredient and / or a pharmaceutically acceptable salt thereof, and to the use of such particles in the manufacture of a medicament for use in the treatment and / or prevention of atherosclerosis, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, myocardial infarction.

TR2010/09397A 2010-05-04 2010-11-11 Pharmaceutical compositions containing rosuvastatin. TR201009397A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/09397A TR201009397A2 (en) 2010-11-11 2010-11-11 Pharmaceutical compositions containing rosuvastatin.
EP11725996A EP2566465A2 (en) 2010-05-04 2011-05-03 Stable rosuvastatin formulations
PCT/TR2011/000135 WO2011139256A2 (en) 2010-05-04 2011-05-03 Stable rosuvastatin formulations
PCT/TR2011/000249 WO2012064307A1 (en) 2010-11-11 2011-11-03 Pharmaceutical compositions comprising rosuvastatin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09397A TR201009397A2 (en) 2010-11-11 2010-11-11 Pharmaceutical compositions containing rosuvastatin.

Publications (1)

Publication Number Publication Date
TR201009397A2 true TR201009397A2 (en) 2012-05-21

Family

ID=45446165

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09397A TR201009397A2 (en) 2010-05-04 2010-11-11 Pharmaceutical compositions containing rosuvastatin.

Country Status (2)

Country Link
TR (1) TR201009397A2 (en)
WO (1) WO2012064307A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201009399A2 (en) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rapidly soluble effervescent rosuvastatin formulations.
US10376470B2 (en) 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
SI2844233T1 (en) 2012-05-01 2020-08-31 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
EP2692354A1 (en) 2012-08-03 2014-02-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Means for treating heart disease
KR20150079373A (en) 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
US10413543B2 (en) 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
CZ2016539A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
CN108245516B (en) * 2017-11-09 2019-04-12 浙江京新药业股份有限公司 A kind of pharmaceutical composition and preparation method thereof containing rosuvastain calcium

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217629B (en) 1991-12-12 2000-03-28 Novartis Ag. Process for producing stabilized pharmaceutical compositions comprising fluvastatin
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP2066644A2 (en) 2006-08-04 2009-06-10 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
EP2120882A2 (en) * 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
ES2657416T3 (en) 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
EP2216020A1 (en) * 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations

Also Published As

Publication number Publication date
WO2012064307A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
TR201009397A2 (en) Pharmaceutical compositions containing rosuvastatin.
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
EA201201050A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
PH12015501156A1 (en) Pharmaceutical compositions
IN2013CN01340A (en)
MD4556B1 (en) Catechol O-methyltransferase activity inhibiting compounds
UA113538C2 (en) FLUOROMETHYL-5,6-DIHYDRO-4H- $ 1,3] OXAZINES
MA44637B1 (en) Heterocyclic compounds and their uses
PH12015502365B1 (en) Bace1 inhibitors
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
EA201690679A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPIPIN AND VALSARTAN
JO3524B1 (en) Injectable preparation
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
TR201001417A1 (en) Cefdinir formulation with improved dissolution rate
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
TR201009394A2 (en) Improved montelukast formulations.
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
TN2016000207A1 (en) Pharmaceutical dosage forms.
MY160904A (en) Piperazines as antimalarial agents
TR201007926A1 (en) Prasugrel tablet formulations.
TR201815617A2 (en) A formulation containing dexketoprofen.
IN2014CN04119A (en)
TR201009399A2 (en) Rapidly soluble effervescent rosuvastatin formulations.